alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest studies

Every summary in our library, newest first, as a dated timeline.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 7,226–7,250 of 27,380 studies, newest first · page 290 of 1096.

November 2023 4

  1. 2023-11-01

    Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease

    ✓ Peer-reviewed Treatments The New England journal of medicine

    Key finding: Among persons with early Alzheimer's disease, the use of gantenerumab led to a lower amyloid plaque burden than placebo at 116 weeks but was not associated with slower clinical decline. +1 more finding

    Full summary, score breakdown and related studies → Original source

  2. 2023-11-01

    Economic Evaluation of Exercise or Cognitive and Social Enrichment Activities for Improved Cognition After Stroke

    ✓ Peer-reviewed Treatments JAMA network open

    Key finding: Physical exercise and cognitive and social enrichment activities can enhance cognitive function in patients with chronic stroke, but their cost-effectiveness compared with a balance and tone program is uncertain. +4 more findings

    Full summary, score breakdown and related studies → Original source

  3. 2023-11-01

    Plasma Biomarkers of Alzheimer Disease in Women With and Without HIV

    ✓ Peer-reviewed Biomarkers JAMA network open

    Key finding: These findings suggest that increases in certain plasma AD biomarkers are associated with NP in WLWH and WLWOH and may be associated with later onset of AD, and measuring these biomarkers could be a pivotal advancement in monitoring aging brain health and development of AD among women with and without HIV. +4 more findings

    Full summary, score breakdown and related studies → Original source

  4. 2023-11-01

    Tau Oligomer-Containing Synapse Elimination by Microglia and Astrocytes in Alzheimer Disease

    ✓ Peer-reviewed Biomarkers JAMA neurology

    Key finding: Of 40 included participants (mean [SD] age at death, 88 [8] years; 21 [52%] male), 19 had early-stage dementia with Braak stages III to IV, 13 had resilient brains with similar Braak stages III to IV, and 8 had no dementia (Braak stages 0-II). +3 more findings

    Full summary, score breakdown and related studies → Original source

October 2023 21

  1. 2023-10-30

    The Pathogenesis in Alzheimer's Disease: TREM2 as a Potential Target

    ✓ Peer-reviewed TREM2 and immune genetics Journal of integrative neuroscience

    Key finding: It is associated with the deposition of extracellular amyloid-β (Aβ) in neural plaques (NPs), as well as intracellular hyperphosphorylated tau proteins that form neurofibrillary tangles (NFTs).

    Full summary, score breakdown and related studies → Original source

  2. 2023-10-30

    Trem2 promotes foamy macrophage lipid uptake and survival in atherosclerosis

    ✓ Peer-reviewed TREM2 and immune genetics Nature cardiovascular research

    Key finding: Factors regulating foamy macrophage differentiation and survival in plaque remain poorly understood. +3 more findings

    Full summary, score breakdown and related studies → Original source

  3. 2023-10-28

    Clearance of interstitial fluid (ISF) and CSF (CLIC) group-part of Vascular Professional Interest Area (PIA), updates in 2022-2023. Cerebrovascular disease and the failure of elimination of Amyloid-β from the brain and retina with age and Alzheimer's disease: Opportunities for therapy

    ✓ Peer-reviewed Treatments Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: The overarching objectives of the CLIC group are to: (1) understand the age-related physiology changes that underlie impaired clearance of interstitial fluid (ISF) and cerebrospinal fluid (CSF) (CLIC); (2) understand the cellular and molecular mechanisms underlying intramural periarterial drainage (IPAD) in the brain; (3) establish novel diagnostic tests for Alzheimer's disease (AD), cerebral amyloid angiopathy (CAA), retinal amyloid vasculopathy, amyloid-related imaging abnormalities (ARIA) of spontaneous and iatrogenic CAA-related inflammation (CAA-ri), and vasomotion; and (4) establish novel therapies that facilitate IPAD to eliminate amyloid β (Aβ) from the aging brain and retina, to prevent or reduce AD and CAA pathology and ARIA side events associated with AD immunotherapy.

    Full summary, score breakdown and related studies → Original source

  4. 2023-10-27

    Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA

    ✓ Peer-reviewed Treatments Journal of clinical medicine

    Key finding: This could lead to improved risk stratification and the ultimate reduction of symptomatic ARIA. +4 more findings

    Full summary, score breakdown and related studies → Original source

  5. 2023-10-26

    Detection Rates of Mild Cognitive Impairment in Primary Care for the United States Medicare Population

    ✓ Peer-reviewed Health systems and care delivery The Journal of Prevention of Alzheimer s Disease

    Key finding: The average detection rates for mild cognitive impairment is 0.08 (interquartile range=0.00-0.02) for both clinicians and practices, suggesting that only about 8% of expected cases were diagnosed on average. +2 more findings

    Full summary, score breakdown and related studies → Original source

  6. 2023-10-25

    Association between ventricular CSF biomarkers and outcome after shunt surgery in idiopathic normal pressure hydrocephalus

    ✓ Peer-reviewed Biomarkers Fluids and barriers of the CNS

    Key finding: The neurogranin concentration was higher in improved (68%) compared to unimproved patients (median 365 ng/L (IQR 186-544) vs 330 (205-456); p = 0.046). +4 more findings

    Full summary, score breakdown and related studies → Original source

  7. 2023-10-25

    Blood Biomarkers in Alzheimer's Disease

    ✓ Peer-reviewed Biomarkers ACS chemical neuroscience

    Key finding: Recent research indicates that oxidative stress (OS) occurs prior to amyloid plaque (Aβ) formation and abnormal tau phosphorylation in AD.

    Full summary, score breakdown and related studies → Original source

  8. 2023-10-25

    Cross-sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease

    ✓ Peer-reviewed Biomarkers Alzheimer's & dementia (Amsterdam, Netherlands)

    Key finding: Plasma GFAP discriminated AD dementia from normal cognition (adjusted mean difference = 0.90 standard deviation [SD]) and mild cognitive impairment (adjusted mean difference = 0.72 SD), and demonstrated superior discrimination compared to alternative plasma biomarkers. +3 more findings

    Full summary, score breakdown and related studies → Original source

  9. 2023-10-25

    Risk factors associated with post-acute sequelae of SARS-CoV-2: an N3C and NIH RECOVER study

    ✓ Peer-reviewed Disparities BMC public health

    Key finding: The objective is to identify risk factors associated with PASC/long-COVID diagnosis. +4 more findings

    Full summary, score breakdown and related studies → Original source

  10. 2023-10-25

    Effect of Individual Virtual Reality Cognitive Training Programs on Cognitive Function and Depression in Middle-Aged Women: Randomized Controlled Trial

    ✓ Peer-reviewed Treatments JMIR mental health

    Key finding: These programs are considered beneficial nonpharmacological cognitive training interventions for middle-aged women at high risk of cognitive impairment.

    Full summary, score breakdown and related studies → Original source

  11. 2023-10-25

    Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease

    ✓ Peer-reviewed Treatments Annals of neurology

    Key finding: Differential eligibility may contribute to underrepresentation of some minoritized racial and ethnic groups in early AD trials. +1 more finding

    Full summary, score breakdown and related studies → Original source

  12. 2023-10-25

    Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease

    ✓ Peer-reviewed Biomarkers Annals of neurology

    Key finding: Across 3 study samples, combining the functional connectome and molecular properties substantially enhanced the explanatory power compared to single modalities, providing a valuable tool to explain regional susceptibility to tau deposition in AD. +2 more findings

    Full summary, score breakdown and related studies → Original source

  13. 2023-10-24

    Huntington's Disease Drug Development: A Phase 3 Pipeline Analysis

    ✓ Peer-reviewed Clinical trials Pharmaceuticals (Basel, Switzerland)

    Key finding: The disorder is a result of a trinucleotide repeat expansion mutation that is inherited in an autosomal dominant manner.

    Full summary, score breakdown and related studies → Original source

  14. 2023-10-24

    Tau-targeting therapies for Alzheimer disease: current status and future directions

    ✓ Peer-reviewed Drug development Nature reviews. Neurology

    Key finding: AD is characterized pathologically by amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the brain, with associated loss of synapses and neurons, which eventually results in dementia. +1 more finding

    Full summary, score breakdown and related studies → Original source

  15. 2023-10-24

    Plasma biomarkers predict Alzheimer's disease before clinical onset in Chinese cohorts

    ✓ Peer-reviewed Biomarkers Nature communications

    Key finding: Plasma Aβ42, p-tau181, and NfL were significantly correlated with cerebrospinal fluid counterparts and significantly altered in participants with preclinical AD. +1 more finding

    Full summary, score breakdown and related studies → Original source

  16. 2023-10-24

    Tango-therapy vs physical exercise in older people with dementia; a randomized controlled trial

    ✓ Peer-reviewed Treatments BMC geriatrics

    Key finding: After 3 months, IG improved gait speed (p = 0.016), implying a statistically significant difference between groups in favour of IG (p = 0.003). +2 more findings

    Full summary, score breakdown and related studies → Original source

  17. 2023-10-24

    Neuroprotection elicited by taurine in sporadic Alzheimer-like disease: benefits on memory and control of neuroinflammation in the hippocampus of rats

    ✓ Peer-reviewed Biomarkers Molecular and cellular biochemistry

    Key finding: In conclusion, these findings demonstrate that taurine is able to enhance memory, up-regulates IR in the hippocampus, protects the neuron population, and reduces the astrogliosis found in SDAT.

    Full summary, score breakdown and related studies → Original source

  18. 2023-10-23

    Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis

    ✓ Peer-reviewed Drug development Diabetes, obesity & metabolism

    Key finding: Metformin, thiazolidinediones, pioglitazone, GLP1RAs and SGLT2is were associated with reduced risk of dementia. +4 more findings

    Full summary, score breakdown and related studies → Original source

  19. 2023-10-23

    Alzheimer's disease and epilepsy: shared neuropathology guides current and future treatment strategies

    ✓ Peer-reviewed Treatments Frontiers in neurology

    Key finding: Additionally, there are practical treatment considerations in patients with co-morbid AD and epilepsy-namely, there is a higher risk of seizures associated with medications commonly prescribed for Alzheimer's disease patients, including antidepressants and antipsychotics such as trazodone, serotonin norepinephrine reuptake inhibitors (SNRIs), and first-generation neuroleptics. +1 more finding

    Full summary, score breakdown and related studies → Original source

  20. 2023-10-23

    Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial

    ✓ Peer-reviewed Biomarkers Alzheimer's research & therapy

    Key finding: These findings suggest a benefit of MI plus omega 3 in positive blood amyloid subjects. +3 more findings

    Full summary, score breakdown and related studies → Original source

  21. 2023-10-22

    Retinal microvasculature and incident dementia over 10 years: The Three-City-Alienor cohort

    ✓ Peer-reviewed Brain scans and imaging Alzheimer's & dementia (Amsterdam, Netherlands)

    Key finding: One hundred twenty-eight participants (21.9%) developed dementia over a median of 7.1 years. +4 more findings

    Full summary, score breakdown and related studies → Original source

Browse the library by subject, with the full score breakdown →